December 2026

MEDPACE Clinical Pharmacology

CIN-111-111 Cohort 2
Non-Sentinels

Study Inpatient dates:
Dec 14-18, 2026

Study Outpatient dates:
Dec 21 and 28, 2026

Sun	Mon	Tue	Wed	Thu	Fri	Sat
		1	2	3	4	5 **Day –10 ABPM Window Starts**
6	7	8 **Day –7 ABPM Window Ends**	9	10	11	12 Begin strenuous exercise restriction
13 Begin overnight fast	14 **Day –1 Admission** Begin exercise, caffeine, and alcohol restrictions	15 **Day 1 Dose** Begin sperm donation restriction	16 **Day 2 Inpatient**	17 **Day 3 Inpatient**	18 **Day 4 Discharge** **Payment 1***	19 Begin strenuous exercise restriction
20 Begin overnight fast	21 **Day 7 OPV** Begin exercise, caffeine, and alcohol restrictions	22	23	24	25 **Christmas**	26 Begin strenuous exercise restriction
27 Begin overnight fast	28 **Day 14 OPV** **Payment 2*** Begin exercise, caffeine, and alcohol restrictions	29	30	31		

Instructions / Restrictions:

- Continue to follow contraception requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding
- Abstain from sperm donation from Day 1 through the end of the study
- Must not have any surgery within 4 weeks prior to Day 1 and must not plan to during study
- Avoid donation of blood/blood products within 2 months prior to Day 1 and throughout the study
- Must not routinely consume >2 units of alcohol/day and/or is unwilling or unable to limit alcohol consumption throughout the study
- Must not have a history of alcohol or substance abuse (licit or illicit) within the last 12 months before Screening.
- Must not use nicotine or tobacco-containing products (including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) during 6 months before Day 1 of study, or during study
- Abstain from use of illicit drugs throughout the study
- **Abstain from exercise, smoking, caffeine, and alcohol for 30 minutes prior to each visit**
- **Abstain from strenuous exercise for 48 hours before each visit**
- Must not receive any investigational agent within 30 days or 5 half-lives prior to Day 1, or be in follow-up of another clinical study before enrolling in this one
- Must not be a third shift or night shift worker
- Avoid use of RAAS-targeting rescue medications including ACE-inhibitors, ARBs, and Aldosterone Receptor Blockers (also referred to as MCRAs and MRAs) and renin inhibitors throughout the study
- Avoid any vaccination (including a booster) within 2 weeks prior to Day 1 and during study
- Avoid use of the following prescription medications within 30 days before Day 1 or during study:
  a. Hormone replacement therapy (eg, estrogen, thyroid), PO contraceptives, proton pump inhibitors, histamine H2-receptor antagonists, antidepressants, and HMG-CoA reductase inhibitors (statins) will be allowed if subject is on stable therapy (at the discretion of investigator).
  b. Inhaler therapy for asthma is permitted if the subject is on stable therapy, uses short acting beta agonists to relieve symptoms no more than 2 days a week, and has had no exacerbations requiring oral glucocorticoids in the preceding year.
  c. Pending approval, certain topical medications may be permitted if their application around injection sites can be avoided.
  d. Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed. The chronic use of NSAIDs is not permitted.
  e. GLP-1s are not permitted.
- Fast overnight for at least 10 hours (water allowed) prior to Screening, Admission (Day –1), and all outpatient visits.

ABPM VISIT: After vital signs and other labs/clinical procedures, a 24 hour blood pressure cuff and monitor will be placed on you, and you will spend the night in a nearby hotel. Your blood pressure will be taken every 20-30 minutes. You will return the equipment the next morning.

Reminder: Breath alcohol & urine drug test at each visit. COVID-19 rapid antigen test at Admission (Day -1) only.

***Payment to occur within 48 hours after payment visit day**

January 2027

MEDPACE Clinical Pharmacology

CIN-111-111 Cohort 2
Non-Sentinels

Study Outpatient dates:
Jan 04 and 11, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
					1 New Year's Day	**2** Begin strenuous exercise restriction
3 Begin overnight fast	**4** **Day 21 OPV** Begin exercise, caffeine, and alcohol restrictions	**5**	**6**	**7**	**8**	**9** Begin strenuous exercise restriction
10 Begin overnight fast	**11** **Day 28 OPV** **Payment 3*** Begin exercise, caffeine, and alcohol restrictions	**12**	**13**	**14**	**15**	**16**
17	**18**	**19**	**20**	**21**	**22**	**23**
24	**25**	**26**	**27**	**28**	**29**	**30**
31						

Instructions / Restrictions:

- Continue to follow contraception requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding
- Abstain from sperm donation from Day 1 through the end of the study
- Must not have any surgery within 4 weeks prior to Day 1 and must not plan to during study
- Avoid donation of blood/blood products within 2 months prior to Day 1 and throughout the study
- Must not routinely consume >2 units of alcohol/day and/or is unwilling or unable to limit alcohol consumption throughout the study
- Must not have a history of alcohol or substance abuse (licit or illicit) within the last 12 months before Screening.
- Must not use nicotine or tobacco-containing products (including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) during 6 months before Day 1 of study, or during study
- Abstain from use of illicit drugs throughout the study
- **Abstain from exercise, smoking, caffeine, and alcohol for 30 minutes prior to each visit**
- **Abstain from strenuous exercise for 48 hours before each visit**
- Must not receive any investigational agent within 30 days or 5 half-lives prior to Day 1, or be in follow-up of another clinical study before enrolling in this one
- Must not be a third shift or night shift worker
- Avoid use of RAAS-targeting rescue medications including ACE-inhibitors, ARBs, and Aldosterone Receptor Blockers (also referred to as MCRAs and MRAs) and renin inhibitors throughout the study
- Avoid any vaccination (including a booster) within 2 weeks prior to Day 1 and during study
- Avoid use of the following prescription medications within 30 days before Day 1 or during study:
  a. Hormone replacement therapy (eg, estrogen, thyroid), PO contraceptives, proton pump inhibitors, histamine H2-receptor antagonists, antidepressants, and HMG-CoA reductase inhibitors (statins) will be allowed if subject is on stable therapy (at the discretion of investigator).
  b. Inhaler therapy for asthma is permitted if the subject is on stable therapy, uses short acting beta agonists to relieve symptoms no more than 2 days a week, and has had no exacerbations requiring oral glucocorticoids in the preceding year.
  c. Pending approval, certain topical medications may be permitted if their application around injection sites can be avoided.
  d. Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed. The chronic use of NSAIDs is not permitted.
  e. GLP-1s are not permitted.
- Fast overnight for at least 10 hours (water allowed) prior to Screening, Admission (Day –1), and all outpatient visits.

Reminder: Breath alcohol & urine drug test at each visit. COVID-19 rapid antigen test at Admission (Day -1) only.

***Payment to occur within 48 hours after payment visit day**

February 2027

MEDPACE Clinical Pharmacology

CIN-111-111 Cohort 2
Non-Sentinels

Study Outpatient dates:
Feb 08, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
	1	**2**	**3**	**4**	**5**	**6** Begin strenuous exercise restriction
7 Begin overnight fast	**8** **Day 56 OPV** **Payment 4*** Begin exercise, caffeine, and alcohol restrictions	**9**	**10**	**11**	**12**	**13**
14	**15**	**16**	**17**	**18**	**19**	**20**
21	**22**	**23**	**24**	**25**	**26**	**27**
28						

Instructions / Restrictions:

- Continue to follow contraception requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding
- Abstain from sperm donation from Day 1 through the end of the study
- Must not have any surgery within 4 weeks prior to Day 1 and must not plan to during study
- Avoid donation of blood/blood products within 2 months prior to Day 1 and throughout the study
- Must not routinely consume >2 units of alcohol/day and/or is unwilling or unable to limit alcohol consumption throughout the study
- Must not have a history of alcohol or substance abuse (licit or illicit) within the last 12 months before Screening.
- Must not use nicotine or tobacco-containing products (including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) during 6 months before Day 1 of study, or during study
- Abstain from use of illicit drugs throughout the study
- **Abstain from exercise, smoking, caffeine, and alcohol for 30 minutes prior to each visit**
- **Abstain from strenuous exercise for 48 hours before each visit**
- Must not receive any investigational agent within 30 days or 5 half-lives prior to Day 1, or be in follow-up of another clinical study before enrolling in this one
- Must not be a third shift or night shift worker
- Avoid use of RAAS-targeting rescue medications including ACE-inhibitors, ARBs, and Aldosterone Receptor Blockers (also referred to as MCRAs and MRAs) and renin inhibitors throughout the study
- Avoid any vaccination (including a booster) within 2 weeks prior to Day 1 and during study
- Avoid use of the following prescription medications within 30 days before Day 1 or during study:
  a. Hormone replacement therapy (eg, estrogen, thyroid), PO contraceptives, proton pump inhibitors, histamine H2-receptor antagonists, antidepressants, and HMG-CoA reductase inhibitors (statins) will be allowed if subject is on stable therapy (at the discretion of investigator).
  b. Inhaler therapy for asthma is permitted if the subject is on stable therapy, uses short acting beta agonists to relieve symptoms no more than 2 days a week, and has had no exacerbations requiring oral glucocorticoids in the preceding year.
  c. Pending approval, certain topical medications may be permitted if their application around injection sites can be avoided.
  d. Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed. The chronic use of NSAIDs is not permitted.
  e. GLP-1s are not permitted.
- Fast overnight for at least 10 hours (water allowed) prior to Screening, Admission (Day –1), and all outpatient visits.

Reminder: Breath alcohol & urine drug test at each visit. COVID-19 rapid antigen test at Admission (Day -1) only.

***Payment to occur within 48 hours after payment visit day**

March 2027

MEDPACE Clinical Pharmacology

CIN-111-111 Cohort 2
Non-Sentinels

Study Outpatient dates:
Mar 08, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
	1	**2**	**3**	**4**	**5**	**6** Begin strenuous exercise restriction
7 Begin overnight fast	**8** **Day 84 OPV** **Payment 5*** **ABPM VISIT** Begin exercise, caffeine, and alcohol restrictions	**9**	**10**	**11**	**12**	**13**
14	**15**	**16**	**17**	**18**	**19**	**20**
21	**22**	**23**	**24**	**25**	**26**	**27**
28	**29**	**30**	**31**			

Instructions / Restrictions:

- Continue to follow contraception requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding
- Abstain from sperm donation from Day 1 through the end of the study
- Must not have any surgery within 4 weeks prior to Day 1 and must not plan to during study
- Avoid donation of blood/blood products within 2 months prior to Day 1 and throughout the study
- Must not routinely consume >2 units of alcohol/day and/or is unwilling or unable to limit alcohol consumption throughout the study
- Must not have a history of alcohol or substance abuse (licit or illicit) within the last 12 months before Screening.
- Must not use nicotine or tobacco-containing products (including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) during 6 months before Day 1 of study, or during study
- Abstain from use of illicit drugs throughout the study
- **Abstain from exercise, smoking, caffeine, and alcohol for 30 minutes prior to each visit**
- **Abstain from strenuous exercise for 48 hours before each visit**
- Must not receive any investigational agent within 30 days or 5 half-lives prior to Day 1, or be in follow-up of another clinical study before enrolling in this one
- Must not be a third shift or night shift worker
- Avoid use of RAAS-targeting rescue medications including ACE-inhibitors, ARBs, and Aldosterone Receptor Blockers (also referred to as MCRAs and MRAs) and renin inhibitors throughout the study
- Avoid any vaccination (including a booster) within 2 weeks prior to Day 1 and during study
- Avoid use of the following prescription medications within 30 days before Day 1 or during study:
  a. Hormone replacement therapy (eg, estrogen, thyroid), PO contraceptives, proton pump inhibitors, histamine H2-receptor antagonists, antidepressants, and HMG-CoA reductase inhibitors (statins) will be allowed if subject is on stable therapy (at the discretion of investigator).
  b. Inhaler therapy for asthma is permitted if the subject is on stable therapy, uses short acting beta agonists to relieve symptoms no more than 2 days a week, and has had no exacerbations requiring oral glucocorticoids in the preceding year.
  c. Pending approval, certain topical medications may be permitted if their application around injection sites can be avoided.
  d. Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed. The chronic use of NSAIDs is not permitted.
  e. GLP-1s are not permitted.
- Fast overnight for at least 10 hours (water allowed) prior to Screening, Admission (Day –1), and all outpatient visits.

ABPM VISIT: After vital signs and other labs/clinical procedures, a 24 hour blood pressure cuff and monitor will be placed on you, and you will spend the night in a nearby hotel. Your blood pressure will be taken every 20-30 minutes. You will return the equipment the next morning.

Reminder: Breath alcohol & urine drug test at each visit. COVID-19 rapid antigen test at Admission (Day -1) only.

***Payment to occur within 48 hours after payment visit day**

April 2027

MEDPACE Clinical Pharmacology

CIN-111-111 Cohort 2
Non-Sentinels

Study Outpatient dates:
Apr 05, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
				1	2	3 Begin strenuous exercise restriction
4 Begin overnight fast	5 **Week 16 OPV** **Payment 6*** Begin exercise, caffeine, and alcohol restrictions	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	

Instructions / Restrictions:

- Continue to follow contraception requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding
- Abstain from sperm donation from Day 1 through the end of the study
- Must not have any surgery within 4 weeks prior to Day 1 and must not plan to during study
- Avoid donation of blood/blood products within 2 months prior to Day 1 and throughout the study
- Must not routinely consume >2 units of alcohol/day and/or is unwilling or unable to limit alcohol consumption throughout the study
- Must not have a history of alcohol or substance abuse (licit or illicit) within the last 12 months before Screening.
- Must not use nicotine or tobacco-containing products (including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) during 6 months before Day 1 of study, or during study
- Abstain from use of illicit drugs throughout the study
- **Abstain from exercise, smoking, caffeine, and alcohol for 30 minutes prior to each visit**
- **Abstain from strenuous exercise for 48 hours before each visit**
- Must not receive any investigational agent within 30 days or 5 half-lives prior to Day 1, or be in follow-up of another clinical study before enrolling in this one
- Must not be a third shift or night shift worker
- Avoid use of RAAS-targeting rescue medications including ACE-inhibitors, ARBs, and Aldosterone Receptor Blockers (also referred to as MCRAs and MRAs) and renin inhibitors throughout the study
- Avoid any vaccination (including a booster) within 2 weeks prior to Day 1 and during study
- Avoid use of the following prescription medications within 30 days before Day 1 or during study:
  a. Hormone replacement therapy (eg, estrogen, thyroid), PO contraceptives, proton pump inhibitors, histamine H2-receptor antagonists, antidepressants, and HMG-CoA reductase inhibitors (statins) will be allowed if subject is on stable therapy (at the discretion of investigator).
  b. Inhaler therapy for asthma is permitted if the subject is on stable therapy, uses short acting beta agonists to relieve symptoms no more than 2 days a week, and has had no exacerbations requiring oral glucocorticoids in the preceding year.
  c. Pending approval, certain topical medications may be permitted if their application around injection sites can be avoided.
  d. Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed. The chronic use of NSAIDs is not permitted.
  e. GLP-1s are not permitted.
- Fast overnight for at least 10 hours (water allowed) prior to Screening, Admission (Day –1), and all outpatient visits.

Reminder: Breath alcohol & urine drug test at each visit. COVID-19 rapid antigen test at Admission (Day -1) only.

***Payment to occur within 48 hours after payment visit day**

May 2027

MEDPACE Clinical Pharmacology

CIN-111-111 Cohort 2
Non-Sentinels

Study Outpatient dates:
May 03 and 31, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
						1 Begin strenuous exercise restriction
2 Begin overnight fast	**3** **Week 20 OPV** **Payment 7*** Begin exercise, caffeine, and alcohol restrictions	**4**	**5**	**6**	**7**	**8**
9	**10**	**11**	**12**	**13**	**14**	**15**
16	**17**	**18**	**19**	**20**	**21**	**22**
23	**24**	**25**	**26**	**27**	**28**	**29** Begin strenuous exercise restriction
30 Begin overnight fast	**31** **Memorial Day** **Week 24 OPV** **Payment 8*** **ABPM VISIT** Begin exercise, caffeine, and alcohol restrictions					

Instructions / Restrictions:

- Continue to follow contraception requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding
- Abstain from sperm donation from Day 1 through the end of the study
- Must not have any surgery within 4 weeks prior to Day 1 and must not plan to during study
- Avoid donation of blood/blood products within 2 months prior to Day 1 and throughout the study
- Must not routinely consume >2 units of alcohol/day and/or is unwilling or unable to limit alcohol consumption throughout the study
- Must not have a history of alcohol or substance abuse (licit or illicit) within the last 12 months before Screening.
- Must not use nicotine or tobacco-containing products (including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) during 6 months before Day 1 of study, or during study
- Abstain from use of illicit drugs throughout the study
- **Abstain from exercise, smoking, caffeine, and alcohol for 30 minutes prior to each visit**
- **Abstain from strenuous exercise for 48 hours before each visit**
- Must not receive any investigational agent within 30 days or 5 half-lives prior to Day 1, or be in follow-up of another clinical study before enrolling in this one
- Must not be a third shift or night shift worker
- Avoid use of RAAS-targeting rescue medications including ACE-inhibitors, ARBs, and Aldosterone Receptor Blockers (also referred to as MCRAs and MRAs) and renin inhibitors throughout the study
- Avoid any vaccination (including a booster) within 2 weeks prior to Day 1 and during study
- Avoid use of the following prescription medications within 30 days before Day 1 or during study:
  a. Hormone replacement therapy (eg, estrogen, thyroid), PO contraceptives, proton pump inhibitors, histamine H2-receptor antagonists, antidepressants, and HMG-CoA reductase inhibitors (statins) will be allowed if subject is on stable therapy (at the discretion of investigator).
  b. Inhaler therapy for asthma is permitted if the subject is on stable therapy, uses short acting beta agonists to relieve symptoms no more than 2 days a week, and has had no exacerbations requiring oral glucocorticoids in the preceding year.
  c. Pending approval, certain topical medications may be permitted if their application around injection sites can be avoided.
  d. Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed. The chronic use of NSAIDs is not permitted.
  e. GLP-1s are not permitted.
- Fast overnight for at least 10 hours (water allowed) prior to Screening, Admission (Day –1), and all outpatient visits.

ABPM VISIT: After vital signs and other labs/clinical procedures, a 24 hour blood pressure cuff and monitor will be placed on you, and you will spend the night in a nearby hotel. Your blood pressure will be taken every 20-30 minutes. You will return the equipment the next morning.

Reminder: Breath alcohol & urine drug test at each visit. COVID-19 rapid antigen test at Admission (Day -1) only.

***Payment to occur within 48 hours after payment visit day**

June 2027

MEDPACE Clinical Pharmacology

CIN-111-111 Cohort 2
Non-Sentinels

Study Outpatient dates:
Jun 28, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26 Begin strenuous exercise restriction
27 Begin overnight fast	28 **Week 28 OPV** **Payment 9*** Begin exercise, caffeine, and alcohol restrictions	29	30			

Instructions / Restrictions:

- Continue to follow contraception requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding
- Abstain from sperm donation from Day 1 through the end of the study
- Must not have any surgery within 4 weeks prior to Day 1 and must not plan to during study
- Avoid donation of blood/blood products within 2 months prior to Day 1 and throughout the study
- Must not routinely consume >2 units of alcohol/day and/or is unwilling or unable to limit alcohol consumption throughout the study
- Must not have a history of alcohol or substance abuse (licit or illicit) within the last 12 months before Screening.
- Must not use nicotine or tobacco-containing products (including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) during 6 months before Day 1 of study, or during study
- Abstain from use of illicit drugs throughout the study
- **Abstain from exercise, smoking, caffeine, and alcohol for 30 minutes prior to each visit**
- **Abstain from strenuous exercise for 48 hours before each visit**
- Must not receive any investigational agent within 30 days or 5 half-lives prior to Day 1, or be in follow-up of another clinical study before enrolling in this one
- Must not be a third shift or night shift worker
- Avoid use of RAAS-targeting rescue medications including ACE-inhibitors, ARBs, and Aldosterone Receptor Blockers (also referred to as MCRAs and MRAs) and renin inhibitors throughout the study
- Avoid any vaccination (including a booster) within 2 weeks prior to Day 1 and during study
- Avoid use of the following prescription medications within 30 days before Day 1 or during study:
  a. Hormone replacement therapy (eg, estrogen, thyroid), PO contraceptives, proton pump inhibitors, histamine H2-receptor antagonists, antidepressants, and HMG-CoA reductase inhibitors (statins) will be allowed if subject is on stable therapy (at the discretion of investigator).
  b. Inhaler therapy for asthma is permitted if the subject is on stable therapy, uses short acting beta agonists to relieve symptoms no more than 2 days a week, and has had no exacerbations requiring oral glucocorticoids in the preceding year.
  c. Pending approval, certain topical medications may be permitted if their application around injection sites can be avoided.
  d. Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed. The chronic use of NSAIDs is not permitted.
  e. GLP-1s are not permitted.
- Fast overnight for at least 10 hours (water allowed) prior to Screening, Admission (Day –1), and all outpatient visits.

Reminder: Breath alcohol & urine drug test at each visit. COVID-19 rapid antigen test at Admission (Day -1) only.

***Payment to occur within 48 hours after payment visit day**

July 2027

MEDPACE Clinical Pharmacology

CIN-111-111 Cohort 2
Non-Sentinels

Study Outpatient dates:
Jul 26, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
				1	2	3
4	5 Independence Day Bridge Holiday	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24 Begin strenuous exercise restriction
25 Begin overnight fast	26 **Week 32 OPV** **Payment 10*** Begin exercise, caffeine, and alcohol restrictions	27	28	29	30	31

Instructions / Restrictions:

- Continue to follow contraception requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding
- Abstain from sperm donation from Day 1 through the end of the study
- Must not have any surgery within 4 weeks prior to Day 1 and must not plan to during study
- Avoid donation of blood/blood products within 2 months prior to Day 1 and throughout the study
- Must not routinely consume >2 units of alcohol/day and/or is unwilling or unable to limit alcohol consumption throughout the study
- Must not have a history of alcohol or substance abuse (licit or illicit) within the last 12 months before Screening.
- Must not use nicotine or tobacco-containing products (including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) during 6 months before Day 1 of study, or during study
- Abstain from use of illicit drugs throughout the study
- **Abstain from exercise, smoking, caffeine, and alcohol for 30 minutes prior to each visit**
- **Abstain from strenuous exercise for 48 hours before each visit**
- Must not receive any investigational agent within 30 days or 5 half-lives prior to Day 1, or be in follow-up of another clinical study before enrolling in this one
- Must not be a third shift or night shift worker
- Avoid use of RAAS-targeting rescue medications including ACE-inhibitors, ARBs, and Aldosterone Receptor Blockers (also referred to as MCRAs and MRAs) and renin inhibitors throughout the study
- Avoid any vaccination (including a booster) within 2 weeks prior to Day 1 and during study
- Avoid use of the following prescription medications within 30 days before Day 1 or during study:
  a. Hormone replacement therapy (eg, estrogen, thyroid), PO contraceptives, proton pump inhibitors, histamine H2-receptor antagonists, antidepressants, and HMG-CoA reductase inhibitors (statins) will be allowed if subject is on stable therapy (at the discretion of investigator).
  b. Inhaler therapy for asthma is permitted if the subject is on stable therapy, uses short acting beta agonists to relieve symptoms no more than 2 days a week, and has had no exacerbations requiring oral glucocorticoids in the preceding year.
  c. Pending approval, certain topical medications may be permitted if their application around injection sites can be avoided.
  d. Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed. The chronic use of NSAIDs is not permitted.
  e. GLP-1s are not permitted.
- Fast overnight for at least 10 hours (water allowed) prior to Screening, Admission (Day –1), and all outpatient visits.

Reminder: Breath alcohol & urine drug test at each visit. COVID-19 rapid antigen test at Admission (Day -1) only.

***Payment to occur within 48 hours after payment visit day**

August 2027

MEDPACE Clinical Pharmacology

CIN-111-111 Cohort 2
Non-Sentinels

Study Outpatient dates:
Aug 23, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
1	**2**	**3**	**4**	**5**	**6**	**7**
8	**9**	**10**	**11**	**12**	**13**	**14**
15	**16**	**17**	**18**	**19**	**20**	**21** Begin strenuous exercise restriction
22 Begin overnight fast	**23** **Week 36** **OPV** **Payment 11*** **ABPM VISIT** Begin exercise, caffeine, and alcohol restrictions	**24**	**25**	**26**	**27**	**28**
29	**30**	**31**				

Instructions / Restrictions:

- Continue to follow contraception requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding
- Abstain from sperm donation from Day 1 through the end of the study
- Must not have any surgery within 4 weeks prior to Day 1 and must not plan to during study
- Avoid donation of blood/blood products within 2 months prior to Day 1 and throughout the study
- Must not routinely consume >2 units of alcohol/day and/or is unwilling or unable to limit alcohol consumption throughout the study
- Must not have a history of alcohol or substance abuse (licit or illicit) within the last 12 months before Screening.
- Must not use nicotine or tobacco-containing products (including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) during 6 months before Day 1 of study, or during study
- Abstain from use of illicit drugs throughout the study
- **Abstain from exercise, smoking, caffeine, and alcohol for 30 minutes prior to each visit**
- **Abstain from strenuous exercise for 48 hours before each visit**
- Must not receive any investigational agent within 30 days or 5 half-lives prior to Day 1, or be in follow-up of another clinical study before enrolling in this one
- Must not be a third shift or night shift worker
- Avoid use of RAAS-targeting rescue medications including ACE-inhibitors, ARBs, and Aldosterone Receptor Blockers (also referred to as MCRAs and MRAs) and renin inhibitors throughout the study
- Avoid any vaccination (including a booster) within 2 weeks prior to Day 1 and during study
- Avoid use of the following prescription medications within 30 days before Day 1 or during study:
  a. Hormone replacement therapy (eg, estrogen, thyroid), PO contraceptives, proton pump inhibitors, histamine H2-receptor antagonists, antidepressants, and HMG-CoA reductase inhibitors (statins) will be allowed if subject is on stable therapy (at the discretion of investigator).
  b. Inhaler therapy for asthma is permitted if the subject is on stable therapy, uses short acting beta agonists to relieve symptoms no more than 2 days a week, and has had no exacerbations requiring oral glucocorticoids in the preceding year.
  c. Pending approval, certain topical medications may be permitted if their application around injection sites can be avoided.
  d. Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed. The chronic use of NSAIDs is not permitted.
  e. GLP-1s are not permitted.
- Fast overnight for at least 10 hours (water allowed) prior to Screening, Admission (Day –1), and all outpatient visits.

ABPM VISIT: After vital signs and other labs/clinical procedures, a 24 hour blood pressure cuff and monitor will be placed on you, and you will spend the night in a nearby hotel. Your blood pressure will be taken every 20-30 minutes. You will return the equipment the next morning.

Reminder: Breath alcohol & urine drug test at each visit. COVID-19 rapid antigen test at Admission (Day -1) only.

***Payment to occur within 48 hours after payment visit day**

September 2027

MEDPACE Clinical Pharmacology

CIN-111-111 Cohort 2
Non-Sentinels

Study Outpatient dates:
Sep 20, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
			1	2	3	4
5	6 Labor Day	7	8	9	10	11
12	13	14	15	16	17	18 Begin strenuous exercise restriction
19 Begin overnight fast	20 **Week 40 OPV** **Payment 12*** Begin exercise, caffeine, and alcohol restrictions	21	22	23	24	25
26	27	28	29	30		

Instructions / Restrictions:

- Continue to follow contraception requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding
- Abstain from sperm donation from Day 1 through the end of the study
- Must not have any surgery within 4 weeks prior to Day 1 and must not plan to during study
- Avoid donation of blood/blood products within 2 months prior to Day 1 and throughout the study
- Must not routinely consume >2 units of alcohol/day and/or is unwilling or unable to limit alcohol consumption throughout the study
- Must not have a history of alcohol or substance abuse (licit or illicit) within the last 12 months before Screening.
- Must not use nicotine or tobacco-containing products (including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) during 6 months before Day 1 of study, or during study
- Abstain from use of illicit drugs throughout the study
- **Abstain from exercise, smoking, caffeine, and alcohol for 30 minutes prior to each visit**
- **Abstain from strenuous exercise for 48 hours before each visit**
- Must not receive any investigational agent within 30 days or 5 half-lives prior to Day 1, or be in follow-up of another clinical study before enrolling in this one
- Must not be a third shift or night shift worker
- Avoid use of RAAS-targeting rescue medications including ACE-inhibitors, ARBs, and Aldosterone Receptor Blockers (also referred to as MCRAs and MRAs) and renin inhibitors throughout the study
- Avoid any vaccination (including a booster) within 2 weeks prior to Day 1 and during study
- Avoid use of the following prescription medications within 30 days before Day 1 or during study:
  a. Hormone replacement therapy (eg, estrogen, thyroid), PO contraceptives, proton pump inhibitors, histamine H2-receptor antagonists, antidepressants, and HMG-CoA reductase inhibitors (statins) will be allowed if subject is on stable therapy (at the discretion of investigator).
  b. Inhaler therapy for asthma is permitted if the subject is on stable therapy, uses short acting beta agonists to relieve symptoms no more than 2 days a week, and has had no exacerbations requiring oral glucocorticoids in the preceding year.
  c. Pending approval, certain topical medications may be permitted if their application around injection sites can be avoided.
  d. Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed. The chronic use of NSAIDs is not permitted.
  e. GLP-1s are not permitted.
- Fast overnight for at least 10 hours (water allowed) prior to Screening, Admission (Day –1), and all outpatient visits.

Reminder: Breath alcohol & urine drug test at each visit. COVID-19 rapid antigen test at Admission (Day -1) only.

***Payment to occur within 48 hours after payment visit day**

October 2027

MEDPACE Clinical Pharmacology

CIN-111-111 Cohort 2
Non-Sentinels

Study Outpatient dates:
Oct 18, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16 Begin strenuous exercise restriction
17 Begin overnight fast	18 **Week 44 OPV** **Payment 13*** Begin exercise, caffeine, and alcohol restrictions	19	20	21	22	23
24	25	26	27	28	29	30
31						

Instructions / Restrictions:

- Continue to follow contraception requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding
- Abstain from sperm donation from Day 1 through the end of the study
- Must not have any surgery within 4 weeks prior to Day 1 and must not plan to during study
- Avoid donation of blood/blood products within 2 months prior to Day 1 and throughout the study
- Must not routinely consume >2 units of alcohol/day and/or is unwilling or unable to limit alcohol consumption throughout the study
- Must not have a history of alcohol or substance abuse (licit or illicit) within the last 12 months before Screening.
- Must not use nicotine or tobacco-containing products (including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) during 6 months before Day 1 of study, or during study
- Abstain from use of illicit drugs throughout the study
- **Abstain from exercise, smoking, caffeine, and alcohol for 30 minutes prior to each visit**
- **Abstain from strenuous exercise for 48 hours before each visit**
- Must not receive any investigational agent within 30 days or 5 half-lives prior to Day 1, or be in follow-up of another clinical study before enrolling in this one
- Must not be a third shift or night shift worker
- Avoid use of RAAS-targeting rescue medications including ACE-inhibitors, ARBs, and Aldosterone Receptor Blockers (also referred to as MCRAs and MRAs) and renin inhibitors throughout the study
- Avoid any vaccination (including a booster) within 2 weeks prior to Day 1 and during study
- Avoid use of the following prescription medications within 30 days before Day 1 or during study:
  a. Hormone replacement therapy (eg, estrogen, thyroid), PO contraceptives, proton pump inhibitors, histamine H2-receptor antagonists, antidepressants, and HMG-CoA reductase inhibitors (statins) will be allowed if subject is on stable therapy (at the discretion of investigator).
  b. Inhaler therapy for asthma is permitted if the subject is on stable therapy, uses short acting beta agonists to relieve symptoms no more than 2 days a week, and has had no exacerbations requiring oral glucocorticoids in the preceding year.
  c. Pending approval, certain topical medications may be permitted if their application around injection sites can be avoided.
  d. Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed. The chronic use of NSAIDs is not permitted.
  e. GLP-1s are not permitted.
- Fast overnight for at least 10 hours (water allowed) prior to Screening, Admission (Day –1), and all outpatient visits.

Reminder: Breath alcohol & urine drug test at each visit. COVID-19 rapid antigen test at Admission (Day -1) only.

***Payment to occur within 48 hours after payment visit day**

November 2027

MEDPACE Clinical Pharmacology

CIN-111-111 Cohort 2
Non-Sentinels

Study Outpatient dates:
Nov 15, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
	1	2	3	4	5	6
7	8	9	10	11	12	13 Begin strenuous exercise restriction
14 Begin overnight fast	15 **Week 48 OPV (EOS)** **Payment 14*** **ABPM VISIT** Begin exercise, caffeine, and alcohol restriction	16	17	18	19	20
21	22	23	24	25 **Thanksgiving**	26	27
28	29	30				

Instructions / Restrictions:

- Continue to follow contraception requirements outlined in the informed consent. Must not be pregnant, planning to become pregnant, or breastfeeding
- Abstain from sperm donation from Day 1 through the end of the study
- Must not have any surgery within 4 weeks prior to Day 1 and must not plan to during study
- Avoid donation of blood/blood products within 2 months prior to Day 1 and throughout the study
- Must not routinely consume >2 units of alcohol/day and/or is unwilling or unable to limit alcohol consumption throughout the study
- Must not have a history of alcohol or substance abuse (licit or illicit) within the last 12 months before Screening.
- Must not use nicotine or tobacco-containing products (including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) during 6 months before Day 1 of study, or during study
- Abstain from use of illicit drugs throughout the study
- **Abstain from exercise, smoking, caffeine, and alcohol for 30 minutes prior to each visit**
- **Abstain from strenuous exercise for 48 hours before each visit**
- Must not receive any investigational agent within 30 days or 5 half-lives prior to Day 1, or be in follow-up of another clinical study before enrolling in this one
- Must not be a third shift or night shift worker
- Avoid use of RAAS-targeting rescue medications including ACE-inhibitors, ARBs, and Aldosterone Receptor Blockers (also referred to as MCRAs and MRAs) and renin inhibitors throughout the study
- Avoid any vaccination (including a booster) within 2 weeks prior to Day 1 and during study
- Avoid use of the following prescription medications within 30 days before Day 1 or during study:
  a. Hormone replacement therapy (eg, estrogen, thyroid), PO contraceptives, proton pump inhibitors, histamine H2-receptor antagonists, antidepressants, and HMG-CoA reductase inhibitors (statins) will be allowed if subject is on stable therapy (at the discretion of investigator).
  b. Inhaler therapy for asthma is permitted if the subject is on stable therapy, uses short acting beta agonists to relieve symptoms no more than 2 days a week, and has had no exacerbations requiring oral glucocorticoids in the preceding year.
  c. Pending approval, certain topical medications may be permitted if their application around injection sites can be avoided.
  d. Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed. The chronic use of NSAIDs is not permitted.
  e. GLP-1s are not permitted.
- Fast overnight for at least 10 hours (water allowed) prior to Screening, Admission (Day –1), and all outpatient visits.

ABPM VISIT: After vital signs and other labs/clinical procedures, a 24 hour blood pressure cuff and monitor will be placed on you, and you will spend the night in a nearby hotel. Your blood pressure will be taken every 20-30 minutes. You will return the equipment the next morning.

Reminder: Breath alcohol & urine drug test at each visit. COVID-19 rapid antigen test at Admission (Day -1) only.

***Payment to occur within 48 hours after payment visit day**